Bio Protocol debuts OpenLabs to bypass traditional research grants

The platform functions as a unified interface where researchers can develop concepts, coordinate with contributors, and secure capital without the institutional oversight typical of legacy grant cycles. By integrating AI workflows into the proposal process, Bio Protocol seeks to accelerate project refinement while shifting governance power to the community. Early projects utilizing the infrastructure include RheumaAI, targeting rheumatology, and PeptAI, which focuses on peptide discovery.

Despite the technical expansion, the project faces headwinds from broader market volatility. The BIO token fell over 8% following macroeconomic signals from Federal Reserve Chair Kevin Warsh and geopolitical uncertainty. Beyond market fluctuations, the decentralized science model faces long-term regulatory hurdles. As these projects evolve, they must navigate the complex intersection of tokenized intellectual property, patent law, and pharmaceutical oversight, testing whether decentralized governance can effectively replace established academic and commercial funding frameworks.